Pars Planitis Treatment Global Market Report 2025

The pars planitis treatment market size has grown strongly in recent years. It will grow from $632.88 billion in 2024 to $683.54 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth during the historic period can be attributed to increased awareness of autoimmune eye disorders, a rising incidence of uveitis in pediatric populations, improved access to ophthalmic care, broader use of immunosuppressive therapies, and heightened patient awareness regarding the importance of early intervention.

The pars planitis treatment market size is expected to see strong growth in the next few years. It will grow to $920.48 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth anticipated in the forecast period can be attributed to the increasing adoption of biologic therapies, a rising prevalence of autoimmune diseases, heightened emphasis on pediatric eye care, broader health insurance coverage, and growing demand for personalized treatment approaches. Key trends expected during this period include a shift toward steroid-sparing treatment options, the integration of teleophthalmology in patient management, the development of long-acting drug implants, the use of biosimilars in therapy, and a rising preference for combination treatment strategies.

The rising prevalence of pars planitis is expected to drive the growth of the pars planitis treatment market. Pars planitis is an idiopathic type of intermediate uveitis that causes inflammation in the vitreous and peripheral retina, most commonly affecting people between the ages of 15 and 40. The increase in prevalence is linked to improved awareness and advancements in diagnostic technology, allowing for earlier and more accurate detection. Treatments for pars planitis are essential for managing ocular inflammation, which helps preserve vision and prevent serious complications. These therapies, which include corticosteroids and immunosuppressants, contribute to better long-term eye health and quality of life. As an example, a case report published in February 2025 by the Mega Journal of Case Reports, a U.S.-based medical journal, noted that intermediate uveitis occurs at a rate of 1.4 to 2 cases per 100,000 people, with pars planitis making up 70% of those cases. This increasing occurrence is contributing to the expansion of the treatment market.

Companies in the pars planitis treatment space are focusing on developing advanced therapies, including bispecific antibodies, to improve inflammation control and reduce systemic side effects. Bispecific antibodies are engineered to bind to two different antigens at once, allowing for more targeted and effective treatment. In October 2023, Genentech Inc., a biotechnology company based in the U.S., received FDA approval for Vabysmo (faricimab-svoa) for treating retinal vein occlusion, in addition to its earlier approvals for age-related macular degeneration and diabetic macular edema. Vabysmo is the first bispecific antibody approved for ophthalmic use, targeting both Angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). This dual-action approach helps control inflammation and vascular leakage and is being investigated for treating intermediate uveitis, including pars planitis, where persistent inflammation in the retinal periphery requires precise intervention.

In March 2022, Bausch + Lomb, a healthcare company headquartered in Canada, entered into a partnership with Clearside Biomedical Inc. to commercialize XIPERE in the U.S. for treating macular edema linked to uveitis. The goal of the partnership is to broaden access to XIPERE, which is the first FDA-approved therapy administered via suprachoroidal injection. This delivery method offers a targeted and effective option for the estimated 300,000 Americans affected by uveitis. Clearside Biomedical Inc., based in the U.S., contributes to pars planitis treatment through its involvement with XIPERE.

Major players in the pars planitis treatment market are Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, EyePoint Pharmaceuticals Inc., Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Quantum Cryogenics Ltd., Zimmer MedizinSysteme GmbH, Sun Pharmaceutical Industries Ltd., Hologic Inc., Aurobindo Pharma Limited, Santen Pharmaceutical Co. Ltd., CooperSurgical Inc., AtriCure Inc., Alimera Sciences Inc., and Clearside Biomedical Inc.

North America was the largest region in the pars planitis treatment market in 2024. The regions covered in pars planitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pars planitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pars planitis treatment involves both medical and surgical approaches designed to manage this chronic form of intermediate uveitis, which affects the pars plana region of the eye and may lead to inflammation and potential vision loss. The main objective of treatment is to control ocular inflammation, prevent complications such as macular edema or retinal detachment, and maintain visual function.

The primary treatment options for pars planitis include corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), surgical procedures, cryotherapy, immunomodulatory therapies, and others. Corticosteroids are anti-inflammatory drugs that mimic adrenal gland hormones to reduce swelling, suppress immune activity, and treat inflammation-related conditions. Diagnostic methods include blood tests, X-rays, magnetic resonance imaging (MRI), and others, with treatments administered via oral, intravenous, and other routes. These treatments are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a range of end users including hospitals, clinics, and other healthcare facilities.

The pars planitis treatment market research report is one of a series of new reports that provides pars planitis treatment market statistics, including the pars planitis treatment industry's global market size, regional shares, competitors with an pars planitis treatment market share, detailed pars planitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pars planitis treatment industry. This pars planitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pars planitis treatment market consists of revenues earned by entities by providing services such as diagnosis, pharmacological therapies, surgical interventions, and supportive care management. The market value includes the value of related goods sold by the service provider or included within the service offering. The pars planitis treatment market also includes sales of immunosuppressants, intraocular steroid implants, surgical equipment, and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.